The Pharmacopoeial Discussion Group (PDG), which brings together the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP), held videoconferences on 6 November 2020 and on 12 March 2021. WHO (International Pharmacopoeia) participated as Observer.
By necessity, the first videoconference, a follow-up to the strategic videoconference on 22–23 September 2020, replaced the originally planned annual face-to-face meeting and was dedicated to discussing individual technical items on the PDG work programme.
Individual work programme sign-offs, which were handled by correspondence following this meeting, included major technical revisions to the chapter on X-Ray Powder Diffraction and the monograph for Croscarmellose Sodium. The PDG had also agreed to correction of 7 excipient monographs and correction of sign-off coversheets for 2 excipient monographs. Thus, 28 of the 31 general chapters and 46 of the 60 excipient monographs on its current work programme have now been harmonised among the PDG pharmacopoeias. As ever committed to transparency, the PDG has published the full signed-off texts on each pharmacopoeia’s website (Harmonisation status for General Texts, and Harmonisation status for Excipient monographs).
For more information, read the press release.